Intervacc AB (publ) 2E9

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.

CEO

Mr. Jonas Sohlman

Employees

15

Sector

Healthcare

Industry

Biotechnology

Headquarters

HägerstenSweden

High Today

$0.04

Low Today

$0.04

Open Today

$0.04

Volume Today

0.0

52 Week High

$0.36

52 Week Low

$0.03

Average Volume

0